Market Cap 3.23B
Revenue (ttm) 0.00
Net Income (ttm) -235.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.28
Volume 316,300
Avg Vol 1,181,460
Day's Range N/A - N/A
Shares Out 133.91M
Stochastic %K 78%
Beta 1.57
Analysts Strong Sell
Price Target $33.23

Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive...

Industry: Biotechnology
Sector: Healthcare
Address:
1 Ashley Road, 3rd Floor, Altrincham, United Kingdom
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
Quantumup
Quantumup Oct. 15 at 11:16 AM
UBS⬇️ $HRMY's PT to $43 from $50/⬇️'29 sales ests to $1.08B from $1.34B on Wakix competitive pressures in the NT1/NT2 mkt from pot'l orexin agonists launch. $TAK $ALKS $CNTA ESALY NLSP JAZZ AXSM AVDL UBS said in its note to investors: Based on our buy-side conversations, investors are concerned as HRMY's opportunity to grow into a multi-asset company dwindled with the recent Zygel Ph3 FXS failure (and IH approval rejection). Moreover, it is likely that HRMY's base business Wakix will face competitive pressure in the narcolepsy market with potential orexin agonists launch. We lower our PT to $43 (from $50) based on an unchanged 2.75x multiple on lower 2029E sales of $1.08BN (from $1.34BN) due to the potential competition on Wakix sales and zeroed out Zygel sales. Our PT is supported by DCF.
0 · Reply
Quantumup
Quantumup Oct. 8 at 11:59 AM
Mizuho reiterated $ALKS Outperform/$40 $CNTA $AXSM $TAK Mizuho said in its note: We preview 3Q25 for ALKS and expect slightly above-consensus 3Q25 revenues of $358M (vs. $355M Bloomberg cons) and GAAP EPS of $0.31 (vs. $0.30 cons), driven by potentially above-consensus Aristada and Lybalvi sales. That said, we believe investors are likely more focused on the Vibance-2 Phase 2 readout for alixorexton (ALKS-2680) in narcolepsy type 2 (NT2) this fall. Heading into this readout, we believe the key concerns are potential for high visual AE rates as Vibrance-2 evaluates higher doses (10, 14, 18mg) than 8mg, which demonstrated a significantly higher-than-expected visual AE rate of 29% in the Vibrance-1 NT1 trial. These concerns may be overstated, as NT2/IH patients are likely less hypersensitive to orexin than NT1, and so the visual AE rates may not be as high. Thus, the risk/reward could be skewed to the upside. Maintain $40 PT and OP rating.
0 · Reply
intratio
intratio Oct. 7 at 2:29 PM
$CNTA Centessa Pharmaceuticals plc Our momentum tracker monitors that the price of this stock has an extremely bleak prognosis for the near future and will suffer a highly negative trend that will persist
0 · Reply
Quantumup
Quantumup Oct. 6 at 2:06 PM
Piper Sandler reit'd $ALKS OW-$38 and said: We caught up with Alkermes senior management as part of investor meetings that we hosted in Europe. $CNTA $AXSM $JAZZ $AVDL As we move closer to results from the Phase II Vibrance-2 study in narcolepsy type 2 (NT2) for orexin 2 receptor (OX2R) agonist alixorexton sometime in November (per management expectations), we provide herein a few brief thoughts on what we believe would count as a "win" from the trial. We continue to believe that the underlying size of the treated narcolepsy (narcolepsy type 1 (NT1) and NT2 combined) and idiopathic hypersomnia (IH) populations translates into ample room for a handful of novel OX2R agonists to readily coexist. Beyond that, opportunities for the category beyond sleep/wake are very much under the broader investor radar, though we would keep in mind that visibility into these opportunities (e.g., psychiatric indications) should improve over the next 12-18 months. We reiterate our Overweight rating and $38 PT.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 4:27 PM
$CNTA: Unusual Options Activity Alerted CALL flow observed 88x contracts at Strike price of $25 Exp on 01/16/2026 with Premium of $48K and showing BEARISH Sentiment
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:16 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:06 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
Quantumup
Quantumup Oct. 1 at 11:30 AM
B.Riley🏁 $AXSM Buy/$179 $BMY $JNJ $ALKS $CNTA B.Riley said in its initiation report:
0 · Reply
Quantumup
Quantumup Sep. 30 at 12:21 PM
Stifel reiterated $ALKS Buy-$42 $CNTA $AXSM $JAZZ $AVDL Stifel said: We remain optimistic on the prospects of ALKS2680/alixorexton in NT2, where we think (1) the drug is likely to work, (2) the efficacy bar is actually quite low-drugs historically are only generating ~2-11 minute absolute benefits on MWT and (3) Wall Street safety/ tolerability concerns are overdone. On points #1/2, we think there is a lot of room/ margin in NT2 for ALKS2680 to put up a clinical effect that is materially less than observed in the small ph1b, but still superior to standard-of-care. And on point #3, based on our KOL checks, it has actually been difficult to find a physician who is concerned around visual AEs. The bear case on NT2 is that visual AEs could be worse, but, because these patients have "normal" orexin, efficacy may be more modest -- in our opinion, though, you can't have it both ways.
0 · Reply
Latest News on CNTA
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
Quantumup
Quantumup Oct. 15 at 11:16 AM
UBS⬇️ $HRMY's PT to $43 from $50/⬇️'29 sales ests to $1.08B from $1.34B on Wakix competitive pressures in the NT1/NT2 mkt from pot'l orexin agonists launch. $TAK $ALKS $CNTA ESALY NLSP JAZZ AXSM AVDL UBS said in its note to investors: Based on our buy-side conversations, investors are concerned as HRMY's opportunity to grow into a multi-asset company dwindled with the recent Zygel Ph3 FXS failure (and IH approval rejection). Moreover, it is likely that HRMY's base business Wakix will face competitive pressure in the narcolepsy market with potential orexin agonists launch. We lower our PT to $43 (from $50) based on an unchanged 2.75x multiple on lower 2029E sales of $1.08BN (from $1.34BN) due to the potential competition on Wakix sales and zeroed out Zygel sales. Our PT is supported by DCF.
0 · Reply
Quantumup
Quantumup Oct. 8 at 11:59 AM
Mizuho reiterated $ALKS Outperform/$40 $CNTA $AXSM $TAK Mizuho said in its note: We preview 3Q25 for ALKS and expect slightly above-consensus 3Q25 revenues of $358M (vs. $355M Bloomberg cons) and GAAP EPS of $0.31 (vs. $0.30 cons), driven by potentially above-consensus Aristada and Lybalvi sales. That said, we believe investors are likely more focused on the Vibance-2 Phase 2 readout for alixorexton (ALKS-2680) in narcolepsy type 2 (NT2) this fall. Heading into this readout, we believe the key concerns are potential for high visual AE rates as Vibrance-2 evaluates higher doses (10, 14, 18mg) than 8mg, which demonstrated a significantly higher-than-expected visual AE rate of 29% in the Vibrance-1 NT1 trial. These concerns may be overstated, as NT2/IH patients are likely less hypersensitive to orexin than NT1, and so the visual AE rates may not be as high. Thus, the risk/reward could be skewed to the upside. Maintain $40 PT and OP rating.
0 · Reply
intratio
intratio Oct. 7 at 2:29 PM
$CNTA Centessa Pharmaceuticals plc Our momentum tracker monitors that the price of this stock has an extremely bleak prognosis for the near future and will suffer a highly negative trend that will persist
0 · Reply
Quantumup
Quantumup Oct. 6 at 2:06 PM
Piper Sandler reit'd $ALKS OW-$38 and said: We caught up with Alkermes senior management as part of investor meetings that we hosted in Europe. $CNTA $AXSM $JAZZ $AVDL As we move closer to results from the Phase II Vibrance-2 study in narcolepsy type 2 (NT2) for orexin 2 receptor (OX2R) agonist alixorexton sometime in November (per management expectations), we provide herein a few brief thoughts on what we believe would count as a "win" from the trial. We continue to believe that the underlying size of the treated narcolepsy (narcolepsy type 1 (NT1) and NT2 combined) and idiopathic hypersomnia (IH) populations translates into ample room for a handful of novel OX2R agonists to readily coexist. Beyond that, opportunities for the category beyond sleep/wake are very much under the broader investor radar, though we would keep in mind that visibility into these opportunities (e.g., psychiatric indications) should improve over the next 12-18 months. We reiterate our Overweight rating and $38 PT.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 4:27 PM
$CNTA: Unusual Options Activity Alerted CALL flow observed 88x contracts at Strike price of $25 Exp on 01/16/2026 with Premium of $48K and showing BEARISH Sentiment
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:16 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:06 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
Quantumup
Quantumup Oct. 1 at 11:30 AM
B.Riley🏁 $AXSM Buy/$179 $BMY $JNJ $ALKS $CNTA B.Riley said in its initiation report:
0 · Reply
Quantumup
Quantumup Sep. 30 at 12:21 PM
Stifel reiterated $ALKS Buy-$42 $CNTA $AXSM $JAZZ $AVDL Stifel said: We remain optimistic on the prospects of ALKS2680/alixorexton in NT2, where we think (1) the drug is likely to work, (2) the efficacy bar is actually quite low-drugs historically are only generating ~2-11 minute absolute benefits on MWT and (3) Wall Street safety/ tolerability concerns are overdone. On points #1/2, we think there is a lot of room/ margin in NT2 for ALKS2680 to put up a clinical effect that is materially less than observed in the small ph1b, but still superior to standard-of-care. And on point #3, based on our KOL checks, it has actually been difficult to find a physician who is concerned around visual AEs. The bear case on NT2 is that visual AEs could be worse, but, because these patients have "normal" orexin, efficacy may be more modest -- in our opinion, though, you can't have it both ways.
0 · Reply
Quantumup
Quantumup Sep. 26 at 10:50 AM
RBC Capital⬆️ $ALKS to Outperform-$44 from Sector Perform-$42 and said: Our analysis of potential NT2 treatment effects for alixorexton suggest the drug is likely to show clinically meaningful benefits for patients, with a generally tolerable safety profile. Given the sell-off post NT1 data, and our belief that sentiment continues to be bearish on NT2 and ALKS's potential market positioning, we see a buying opportunity into the NT2 data. While we acknowledge that even though the base business has been more resilient than expected there may still be challenges ahead, and that the company's future is largely anchored to orexin success - adding risk, we still believe shares are undervaluing even modest success in the narcolepsy space. Tgt to $44 from $42 on an increased NT2 PoS and model updates. $CNTA $AXSM $JAZZ $AVDL
0 · Reply
swampwiz0
swampwiz0 Sep. 12 at 4:44 PM
$BNTX Rang the register on a quick 50% return catching the $CNTA falling knife, and moved on to catching the falling knife $BNTX at $93.75.
0 · Reply
candlestickmaster
candlestickmaster Sep. 11 at 3:03 PM
New to this but picked my own play. $CNTA let's see where this goes...
0 · Reply
OptionRunners
OptionRunners Sep. 10 at 6:03 PM
$CNTA flying again today. These are now trading at about $2.00. Opened for a $0.23 credit yesterday.
0 · Reply
swampwiz0
swampwiz0 Sep. 10 at 2:11 PM
$SNPS Just used some of my "falling knife" cash (by exiting $SMMT) to buy this puppy at $400. Got cut a bit in my short time holding $SMMT, but have done very well with $CNTA.
0 · Reply
Doozio
Doozio Sep. 9 at 3:55 PM
$CNTA 🐒🍌🧠⏰♾️
0 · Reply
OptionRunners
OptionRunners Sep. 9 at 3:17 PM
$CNTA October 17th $20C/$30C/$17.50P bull seagulls opening 2,500 times for a $0.23 credit
1 · Reply
swampwiz0
swampwiz0 Sep. 8 at 3:10 PM
$CNTA CHA-CHING!
1 · Reply
WSRX
WSRX Sep. 5 at 11:36 PM
$CNTA think this could be a good sympathy play with ALKS presenting their data very early Monday AM.
0 · Reply
Quantumup
Quantumup Sep. 5 at 11:20 AM
H.C. Wainwright⬆️ $AVDL's PT to $36 from $24, reiterated Buy after Avadel announced that it has entered into an exclusive global license agreement with privately-held XWPharma. $CNTA $ALKS $AXSM $JAZZ H.C. Wainwright added, Valiloxybate has been purposefully designed to deliver the therapeutic benefits of oxybate therapy through a once-at-bedtime, salt-free and artificial sweetener-free formulation. In the wake of this transaction, we reiterate our Buy rating, while raising our 12-month price target to $36 from the prior $24 per share. This reflects the addition of valiloxybate to our valuation assessment. We believe that this candidate could be developed via an even more streamlined clinical pathway than LUMRYZ in both narcolepsy and IH, with potential launch in narcolepsy in 2H28 and in IH in 2029.
1 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 1:00 PM
Wells Fargo has updated their rating for Centessa Pharmaceuticals ( $CNTA ) to Overweight with a price target of 31.
0 · Reply
Quantumup
Quantumup Aug. 29 at 11:36 AM
Oppenheimer resumed $CNTA OP/$40. $ALKS AVDL $AXSM $HRMY $TAK JAZZ ZVRA #WorldSleep2025 Oppenheimer said: We're moving $CNTA to Outperform with a $40PT (prev. Not Rated) based on our conviction for lead asset ORX750 to represent best-in-class potential among orexin-2 receptor (OX2R) agonists, with near-term Ph2a CRYSTAL-1 data in idiopathic hypersomnia (IH) and narcolepsy type-1 and -2 (NT1; NT2) expected this year-likely 4Q25, given c̶t̶.̶g̶o̶v̶ [ Clinicaltrials.gov ] information. Presentations at World Sleep (9/8/2025) for other OX2R agonists should inform the competitive bar for ORX750. We believe the market opportunity for ORX750 is substantial, given: 1) current polypharmacy dynamics; 2) KOL optimism supporting real-world uptake in early treatment lines; and 3) fast-follower positioning allowing $CNTA to benefit from $TAK's commercial buildout. We leverage our narcolepsy coverage (e.g., $AXSM, $HRMY) to inform our analysis, as we forecast $2.5B peak risk-adjusted sales in 2040E.
0 · Reply